Clinical-stage biopharmaceutical company Vir Biotechnology Inc (Nasdaq:VIR) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer.
VIR-5500 is being co-developed by Vir Biotechnology and Astellas Pharma (TYO:4503) under a global strategic collaboration.
The therapy is being evaluated in a Phase 1 study across six dose-expansion cohorts, including monotherapy and combination regimens targeting different stages and treatment settings of prostate cancer.
Earlier Phase 1 data showed that VIR-5500 was generally well tolerated and demonstrated promising anti-tumour activity in patients with metastatic castration-resistant prostate cancer.
Fast Track designation is intended to facilitate and expedite development and review of treatments for serious conditions with unmet medical needs.
Phase 3 trials for VIR-5500 are anticipated to begin in 2027.
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights